TB-500 Peptide Calculator

TB-500 is a synthetic analog of the 17-amino acid active fragment of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid ubiquitous peptide encoded by the TMSB4X gene. Tβ4 is one of the most abundant intracellular proteins in mammalian cells, particularly in platelets, neutrophils, and macrophages, where it maintains the soluble G-actin pool required for rapid cytoskeletal reorganization. The TB-500 fragment retains the core LKKTET actin-binding domain responsible for the majority of Tβ4's biological activity in tissue repair models.

Its low molecular weight (approximately 1,755 Da for the active fragment, versus 4,963 Da for full-length Tβ4) is mechanistically significant. Small peptides diffuse through the extracellular matrix and across tissue planes with minimal steric hindrance, enabling systemic effects following both local and distal administration in animal models. This tissue-penetrating property is a primary reason TB-500 is studied alongside wound repair and remote organ protection protocols. Using a TB-500 calculator ensures accurate BAC water ratios when preparing the higher-volume vials commonly used in this research.

Actin Binding Domain and G-Actin Sequestration

TB-500's primary molecular function is the sequestration of monomeric globular actin (G-actin) through high-affinity binding at its LKKTET motif. The intracellular ratio of G-actin to filamentous F-actin governs whether a cell remains stationary or enters a migratory state. By binding and maintaining a large pool of polymerization-competent G-actin, TB-500 positions cells at the threshold of rapid motility—enabling fast deployment of lamellipodia and filopodia when a migratory signal is received. This mechanism is downstream of Rho GTPase signaling pathways (specifically Rac1 and Cdc42) that coordinate directional cell migration during wound closure and tissue remodeling.

Angiogenesis and Endothelial Cell Differentiation

In endothelial cells, TB-500 promotes angiogenesis through two parallel pathways. First, actin-dependent endothelial cell migration drives the sprouting phase of neovascularization, with TB-500-treated cells in Matrigel assays forming tube-like structures at significantly higher rates than controls. Second, TB-500 upregulates the expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR2, amplifying the angiogenic signaling cascade. The resulting increase in capillary density at injury sites restores oxygen and nutrient delivery—a rate-limiting step in healing of avascular or hypovascular tissues such as tendons, cartilage, and the myocardium.

Collagen Deposition and Anti-inflammatory Activity

TB-500 stimulates the production of extracellular matrix components, particularly type I and type III collagen, by activating fibroblasts at repair sites. Simultaneously, it downregulates the expression of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α through NF-κB pathway inhibition, creating an anti-inflammatory microenvironment that facilitates organized tissue regeneration rather than fibrotic scarring. In cardiac injury models, this combination of angiogenesis induction, cardiomyocyte migration support, and inflammation suppression has produced measurable improvements in ejection fraction metrics.

Common Research Vial Sizes

• 2mg vials: used in small-animal dose-escalation pilots or low-dose maintenance phase studies.
• 5mg vials: standard mid-range format; common in tendon and ligament repair models.
• 10mg vials: the most prevalent TB-500 vial size in active research due to the higher per-dose quantities used in loading-phase protocols. Requires careful BAC water calculation to maintain workable concentration.

TB-500 Dosage Chart: Calculation Example

Use the TB-500 calculator above to verify all values. TB-500 is typically administered at higher absolute doses than peptides such as BPC-157 or Ipamorelin—making concentration accuracy especially important.

This is why researchers commonly use larger BAC water volumes for TB-500: at typical research doses, a concentrated preparation would require drawing nearly a full syringe, reducing measurement precision. Adding 3–4ml BAC water to a 10mg vial lowers concentration and allows more precise volume graduation on the syringe scale.

Handling Protocol

TB-500 is generally more robust than lipidated peptides like Tirzepatide or Semaglutide. Its compact structure resists agitation-induced aggregation more effectively. However, this resilience does not eliminate the need for careful reconstitution—denaturing the LKKTET actin-binding domain through aggressive shaking or excessive heat will still compromise biological activity.

1. 1Equilibrate the TB-500 vial to room temperature (15–20 minutes from refrigerator; 30 minutes from −20°C). Particularly important for 10mg vials where the lyophilized cake is denser.
2. 2Disinfect the vial stopper with a 70% isopropyl alcohol swab. Allow to dry completely before needle insertion.
3. 3Calculate BAC water volume using the TB-500 calculator above. For loading-phase protocols using 10mg vials, consider 3–4ml BAC water to improve dose graduation accuracy.
4. 4Inject BAC water slowly along the inner glass wall. TB-500 dissolves more readily than large lipidated peptides, but controlled injection technique remains best practice.
5. 5Gently swirl until fully dissolved. The solution should be clear and colorless. Refrigerate immediately at 2–8°C.

A distinctive feature of TB-500 preclinical research is the use of biphasic dosing paradigms. Published animal model protocols frequently employ a short-duration loading phase—typically 4–6 weeks of higher-frequency administration—followed by a reduced-frequency maintenance phase. This approach mirrors the pharmacokinetic rationale that initial tissue saturation with Tβ4 requires higher input, while subsequent maintenance of the elevated actin-sequestration pool requires less.

This biphasic structure has direct implications for BAC water preparation and the TB-500 calculator workflow. Loading-phase preparations often involve more frequent vial reconstitutions at higher total doses, while maintenance-phase preparations may require lower concentrations for precise micro-volume dosing. Researchers should calculate BAC water volume separately for each phase to optimize measurement accuracy on their specific syringe size.

• Lyophilized powder at −20°C: Stable for 24–36 months. Recommended for long-term research stock. Minimize freeze-thaw cycles by aliquoting into single-use vials before initial freezing.
• Lyophilized powder at 2–8°C: Stable for 3–6 months. Acceptable for active research batches being accessed regularly.
• Reconstituted solution at 2–8°C: Use within 28–30 days. TB-500 in BAC water is relatively stable within this window due to the benzyl alcohol preservative.
• Extreme heat (above 37°C): Accelerates peptide chain hydrolysis. Do not leave reconstituted vials at room temperature for extended periods. The LKKTET domain is susceptible to thermal denaturation at temperatures approaching physiological range.
• UV light: TB-500 lacks aromatic amino acids with strong UV absorption (no Trp, Tyr) but benzyl alcohol in BAC water undergoes photolytic decomposition under UV, generating benzaldehyde—a potential peptide-reactive species. Store in amber or foil-wrapped vials.

Can TB-500 and BPC-157 be reconstituted in the same vial?

While both TB-500 and BPC-157 are stable in BAC water and have no documented direct chemical incompatibilities, co-reconstitution in a single vial is generally discouraged in strict research settings for several reasons. First, mixed-vial preparations make independent dose titration impossible—if one compound's behavior deviates, it cannot be adjusted without affecting the other. Second, the combined solution's long-term stability has not been formally characterized; inter-peptide interactions (electrostatic, hydrophobic, or aggregation-promoting) cannot be ruled out without specific stability testing. Third, regulatory and publication standards for preclinical research require clearly separated, independently verifiable dose records.

The methodologically sound approach is to reconstitute each peptide in its own vial and draw them sequentially into the same syringe immediately before administration—allowing independent concentration control while achieving co-delivery. This is the standard reflected in most peer-reviewed TB-500 vs BPC-157 research protocols.

Why is the dosage for TB-500 usually higher than other peptides?

TB-500's higher per-dose quantities in animal research stem from its mechanism rather than reduced potency. Because TB-500 acts by maintaining an elevated intracellular G-actin pool across an entire tissue system—rather than triggering a cascade from a single receptor like GPCR-targeted peptides—the effective concentration required to shift the global G-actin:F-actin equilibrium is proportionally higher. Receptor agonists (BPC-157, Ipamorelin) achieve systemic effects from microgram-range doses because signal amplification through second messenger cascades multiplies the initial binding event. G-actin sequestration has no equivalent amplification step; the peptide must be present in sufficient quantity to occupy a meaningful fraction of the available actin pool. The Thymosin Beta-4 dosage chart above (calculated per your specific vial size and BAC water volume) helps translate this higher absolute dose into precise syringe units.